Identification of host or viral parameters that predict off-treatment outcomes in patients chronically infected with the hepatitis B virus by a combination of statistical modelling and bio-informatics approaches. University of Antwerp
Social Epidemiology & Health Policy (SEHPO), Centre for Health Economics Research and Modelling of Infectious Diseases (CHERMID), Laboratory Experimental Medicine and Pediatrics (LEMP)
Chronic Hepatitis B Virus infections affect 3.6% of the worldwide population and result in liver-related death in over 700000 people annually. Current standard of care, consisting of nucleos(t)ide analogues (NA), efficiently suppress viral replication, prevent liver disease, but do not cure the infection, defined as Hepatitis B surface antigen (HBsAg) loss. Lifelong NA treatment is therefore often required. However, in some patients with long ...